Guillain-Barre Syndrome Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Nihon Pharma, Hansa Biopharma, Chafic Karam, Annexon, Inc., Alexion Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Guillain-Barre Syndrome pipeline constitutes 2+ key companies continuously working towards developing 3+ Guillain-Barre Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Guillain-Barre Syndrome Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Guillain-Barre Syndrome Market.

The Guillain-Barre Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Guillain-Barre Syndrome Pipeline Report: https://www.delveinsight.com/sample-request/guillain-barre-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Guillain-Barre Syndrome treatment therapies with a considerable amount of success over the years.
• Guillain-Barre Syndrome companies working in the treatment market are Japan Blood Products Organization, Nihon Pharmaceutical, Hansa Biopharma, Chafic Karam, Annexon, Inc., Alexion Pharmaceuticals, and others, are developing therapies for the Guillain-Barre Syndrome treatment
• Emerging Guillain-Barre Syndrome therapies in the different phases of clinical trials are- GB-0998, NPB-01, Imlifidase, Efgartigimod Alfa-Fcab, ANX005, Eculizumab, and others are expected to have a significant impact on the Guillain-Barre Syndrome market in the coming years.
• In April 2025, A single dose of the investigational drug tanruprubart led to a rapid and sustained improvement in disability for patients with Guillain-Barré syndrome (GBS), according to results from a Phase III placebo-controlled study. The trial's primary endpoint-the GBS Disability Score (GBS-DS) at 8 weeks-revealed that 29% of patients receiving 30 mg/kg of tanruprubart achieved a score of 0 or 1, indicating a return to a healthy state, compared to just 12% in the placebo group (OR 2.41, P=0.0058).
• In January 2025, The FDA has mandated safety labeling updates for both RSV vaccines to include a warning about the rare neurological condition, Guillain-Barré Syndrome (GBS). This decision follows a postmarketing observational study assessing the risk of GBS after vaccination with Abrysvo and Arexvy. After evaluating clinical trial data, reports from the Vaccine Adverse Event Reporting System (VAERS), and findings from the postmarketing study, the FDA concluded that the collective evidence indicates a potential increased risk of GBS with these vaccines. However, the current data is not sufficient to confirm a definitive causal relationship.
• In December 2024, Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on developing late-stage therapies for severe classical complement-mediated neuroinflammatory conditions affecting the body, brain, and eyes, has announced positive topline findings from a real-world evidence (RWE) study supporting the potential of ANX005 as a treatment for Guillain-Barré Syndrome (GBS). GBS is a rapidly progressing neuromuscular disorder that currently lacks any FDA-approved therapies. ANX005, the leading targeted immunotherapy in development for GBS, is designed to deliver a single-dose blockade of C1q and complement activity to stop disease progression during its critical early phase.

Guillain-Barre Syndrome Overview
Guillain-Barre Syndrome (GBS) is a rare, autoimmune neurological disorder in which the body's immune system mistakenly attacks the peripheral nerves. It often begins with weakness or tingling in the legs and can progress to paralysis. GBS is typically triggered by an infection, such as a respiratory or gastrointestinal illness. While most patients recover with medical support, some may experience long-term nerve damage or complications. Treatments like intravenous immunoglobulin (IVIG) and plasma exchange can help reduce symptoms and speed recovery.

Get a Free Sample PDF Report to know more about Guillain-Barre Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/guillain-barre-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Guillain-Barre Syndrome Drugs Under Different Phases of Clinical Development Include:
• GB-0998: Japan Blood Products Organization
• NPB-01: Nihon Pharmaceutical
• Imlifidase: Hansa Biopharma
• Efgartigimod Alfa-Fcab: Chafic Karam
• ANX005: Annexon, Inc.
• Eculizumab: Alexion Pharmaceuticals

Guillain-Barre Syndrome Route of Administration
Guillain-Barre Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Guillain-Barre Syndrome Molecule Type
Guillain-Barre Syndrome Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Guillain-Barre Syndrome Pipeline Therapeutics Assessment
• Guillain-Barre Syndrome Assessment by Product Type
• Guillain-Barre Syndrome By Stage and Product Type
• Guillain-Barre Syndrome Assessment by Route of Administration
• Guillain-Barre Syndrome By Stage and Route of Administration
• Guillain-Barre Syndrome Assessment by Molecule Type
• Guillain-Barre Syndrome by Stage and Molecule Type
DelveInsight's Guillain-Barre Syndrome Report covers around 3+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Guillain-Barre Syndrome product details are provided in the report. Download the Guillain-Barre Syndrome pipeline report to learn more about the emerging Guillain-Barre Syndrome therapies at:
https://www.delveinsight.com/sample-request/guillain-barre-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Guillain-Barre Syndrome Therapeutics Market include:
Key companies developing therapies for Guillain-Barre Syndrome are - Akari Therapeutics, Bayer AG, Mylan N.V., NIHON PHARMACEUTICAL CO. Ltd., Grifols S.A, Octapharma AG, Takeda Pharmaceutical, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Cipla Inc, and others.

Guillain-Barre Syndrome Pipeline Analysis:
The Guillain-Barre Syndrome pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Guillain-Barre Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Guillain-Barre Syndrome Treatment.
• Guillain-Barre Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Guillain-Barre Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Guillain-Barre Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Guillain-Barre Syndrome drugs and therapies-
https://www.delveinsight.com/sample-request/guillain-barre-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Guillain-Barre Syndrome Pipeline Market Drivers
• Rising Incidence and Awareness, Advances in Immunotherapy, Government and Nonprofit Support, Technological Advancements, Unmet Medical Needs, are some of the important factors that are fueling the Guillain-Barre Syndrome Market.

Guillain-Barre Syndrome Pipeline Market Barriers
• However, Complex Disease Pathophysiology, Limited Patient Population, High Treatment Costs, Regulatory Challenges, Lack of Long-Term Data, and other factors are creating obstacles in the Guillain-Barre Syndrome Market growth.

Scope of Guillain-Barre Syndrome Pipeline Drug Insight
• Coverage: Global
• Key Guillain-Barre Syndrome Companies: Japan Blood Products Organization, Nihon Pharmaceutical, Hansa Biopharma, Chafic Karam, Annexon, Inc., Alexion Pharmaceuticals, and others
• Key Guillain-Barre Syndrome Therapies: GB-0998, NPB-01, Imlifidase, Efgartigimod Alfa-Fcab, ANX005, Eculizumab, and others
• Guillain-Barre Syndrome Therapeutic Assessment: Guillain-Barre Syndrome current marketed and Guillain-Barre Syndrome emerging therapies
• Guillain-Barre Syndrome Market Dynamics: Guillain-Barre Syndrome market drivers and Guillain-Barre Syndrome market barriers

Request for Sample PDF Report for Guillain-Barre Syndrome Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/guillain-barre-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Guillain-Barre Syndrome Report Introduction
2. Guillain-Barre Syndrome Executive Summary
3. Guillain-Barre Syndrome Overview
4. Guillain-Barre Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Guillain-Barre Syndrome Pipeline Therapeutics
6. Guillain-Barre Syndrome Late Stage Products (Phase II/III)
7. Guillain-Barre Syndrome Mid Stage Products (Phase II)
8. Guillain-Barre Syndrome Early Stage Products (Phase I)
9. Guillain-Barre Syndrome Preclinical Stage Products
10. Guillain-Barre Syndrome Therapeutics Assessment
11. Guillain-Barre Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Guillain-Barre Syndrome Key Companies
14. Guillain-Barre Syndrome Key Products
15. Guillain-Barre Syndrome Unmet Needs
16 . Guillain-Barre Syndrome Market Drivers and Barriers
17. Guillain-Barre Syndrome Future Perspectives and Conclusion
18. Guillain-Barre Syndrome Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Guillain-Barre Syndrome Epidemiology https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Guillain-Barre Syndrome Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.